UBS Group AG Has $73.28 Million Stock Position in PTC Therapeutics, Inc. $PTCT

Key Points

• UBS Group AG raised its stake in PTC Therapeutics by 113.3% to 964,658 shares — about 1.20% of the company — valued at $73.28 million at quarter-end.
• PTC reported a significant quarterly miss, with EPS of -$1.67 versus consensus -$0.21 and revenue of $164.68 million versus $281.45 million, a 22.7% year-over-year revenue decline.
• Corporate insiders sold a total of 126,492 shares (≈$8.63 million) over the past three months, including transactions by VP Mark Elliott Boulding and Director Stephanie Okey.

UBS Group AG raised its position in PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 113.3% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 964,658 shares of the biopharmaceutical company's stock after purchasing an additional 512,449 shares during the quarter. UBS Group AG owned approximately 1.20% of PTC Therapeutics worth $73,275,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of the company. Smartleaf Asset Management LLC lifted its holdings in shares of PTC Therapeutics by 101.3% during the 3rd quarter. Smartleaf Asset Management LLC now owns 469 shares of the biopharmaceutical company's stock valued at $28,000 after buying an additional 236 shares during the last quarter. Optiver Holding B.V. raised its position in PTC Therapeutics by 96.5% during the third quarter. Optiver Holding B.V. now owns 507 shares of the biopharmaceutical company's stock valued at $31,000 after acquiring an additional 249 shares in the last quarter. Comerica Bank raised its position in PTC Therapeutics by 868.5% during the third quarter. Comerica Bank now owns 523 shares of the biopharmaceutical company's stock valued at $32,000 after acquiring an additional 469 shares in the last quarter. Salomon & Ludwin LLC acquired a new stake in PTC Therapeutics in the fourth quarter valued at approximately $41,000. Finally, First Horizon Corp bought a new stake in PTC Therapeutics in the fourth quarter worth approximately $53,000.

Insider Activity at PTC Therapeutics

In other news, VP Mark Elliott Boulding sold 2,265 shares of the firm's stock in a transaction dated Monday, April 6th. The stock was sold at an average price of $69.45, for a total value of $157,304.25. Following the sale, the vice president directly owned 105,212 shares of the company's stock, valued at approximately $7,306,973.40. This trade represents a 2.11% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Stephanie Okey sold 15,167 shares of the business's stock in a transaction dated Tuesday, March 10th. The stock was sold at an average price of $70.00, for a total value of $1,061,690.00. Following the transaction, the director directly owned 8,000 shares of the company's stock, valued at $560,000. This represents a 65.47% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 126,492 shares of company stock valued at $8,634,621. 5.50% of the stock is owned by corporate insiders.

PTC Therapeutics Price Performance

NASDAQ:PTCT opened at $65.15 on Monday. The company's 50 day moving average is $67.97 and its 200-day moving average is $72.11. PTC Therapeutics, Inc. has a 12 month low of $35.95 and a 12 month high of $87.50. The firm has a market cap of $5.40 billion, a price-to-earnings ratio of 8.42 and a beta of 0.53.

PTC Therapeutics (NASDAQ:PTCT - Get Free Report) last posted its quarterly earnings data on Thursday, February 19th. The biopharmaceutical company reported ($1.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by ($1.46). The firm had revenue of $164.68 million for the quarter, compared to the consensus estimate of $281.45 million. PTC Therapeutics had a negative return on equity of 362.45% and a net margin of 39.44%.PTC Therapeutics's quarterly revenue was down 22.7% on a year-over-year basis. During the same period in the prior year, the company posted ($0.85) earnings per share. Research analysts predict that PTC Therapeutics, Inc. will post -0.74 EPS for the current fiscal year.

Analyst Ratings Changes

Several brokerages have recently commented on PTCT. Royal Bank Of Canada dropped their price target on shares of PTC Therapeutics from $87.00 to $82.00 and set a "sector perform" rating on the stock in a research note on Friday, February 20th. TD Cowen reaffirmed a "hold" rating on shares of PTC Therapeutics in a research note on Thursday, January 29th. Wells Fargo & Company lowered their target price on shares of PTC Therapeutics from $93.00 to $86.00 and set an "overweight" rating on the stock in a research report on Friday, February 20th. Barclays restated an "overweight" rating and set a $120.00 target price on shares of PTC Therapeutics in a report on Monday, February 23rd. Finally, Jefferies Financial Group cut PTC Therapeutics from a "buy" rating to a "hold" rating and reduced their price target for the stock from $91.00 to $76.00 in a research report on Monday, March 30th. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, five have given a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, PTC Therapeutics currently has an average rating of "Moderate Buy" and an average target price of $84.40.

PTC Therapeutics Profile

PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule and biologic therapies for the treatment of rare genetic disorders. Since its founding in 1998, PTC has dedicated its efforts to addressing high unmet medical needs by targeting underlying genetic causes of disease. The company's research platform emphasizes mechanisms such as nonsense suppression and RNA modulation, enabling the development of novel treatments for conditions with limited therapeutic options.

Among PTC's approved products is Translarna (ataluren), a first-in-class therapy designed to treat nonsense mutation Duchenne muscular dystrophy in select markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.